cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Weight Loss Efficacy of and Novo Nordisk's next-gen obesity drug

Despite these limitations, our study provided preliminary evidence that gut microbiota modulation might be a novel mechanism underlying semaglutides therapeutic effects, opening new avenues for personalized T2DM management

The move follows a terminated April 2025 partnership with Novo Nordisk and represents a competitive, lowercost play in telehealth weightloss offerings

The most commonly reported events were decreased appetite (19%), headache (12%), fatigue (11%), and COVID-19 infection (11%), most of which were mild

Between 2007 and 2016, fatalities caused by NAFLD increased from 7.6 to 9.0 per 100,000

Semaglutide is introduced gradually so the body can adjust to its action on the digestive system and on appetite regulation

I was a little nauseous for the first two days, but by the end of week 1, I felt better AND I had lost about 2 lbs